Use of Anti-Idiotypes and Synthetic Peptides for Control of Human T- Lymphotropic Virus Type 3 Infections

Abstract

We have continued our investigation of the potential use of synthetic peptides and anti-idiotypes (anti-Id) for controlling HIV infection. Previous studies have indicated that a peptide corresponding to amino acid sequences 735 to 752 from gp160 induced neutralizing antibodies in rabbits. Mouse monoclonal antibodies were generated to this peptide. These antibodies inhibited cell fusion of divergent HIV-1 isolates but failed to inhibit HIV-2. No neutralization by these monoclonal antibodies was observed in a VSV (HIV-1) pseudotype assay. These data suggest that this region of HIV gp41 may be involved in cell fusion of HIV infected cells with uninfected CD4 positive cells, but not in inhibiting the gp120/CD4 interaction. We have also identified two gp41 synthetic peptides that, when coupled to KLH, exert a profound suppression of normal human proliferative responses to mitogens and allonantigens. These peptides also inhibit normal human NK cell activity in vitro. Similar suppressive effects have been reported previously with a synthetic peptide analogous to amino acid sequences from the feline leukemia virus transmembrane glycoprotein. Mouse monoclonal anti-Ids were generated against an affinity purified chimpanzee anti-gp41 preparation. Keywords: Vaccines, Acquired immune deficiency syndrome.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 28, 1988
Accession Number
ADA204182

Entities

People

  • Ronald C. Kennedy

Organizations

  • Texas Biomedical Research Institute

Tags

DTIC Thesaurus Topics

  • Acquired Immune Deficiency Syndrome
  • Amino Acids
  • Antibodies
  • Biomedical Research
  • Cell Physiological Processes
  • Cells
  • Classification
  • Contracts
  • Hiv Infections
  • Immunization
  • Immunosuppression
  • Infection
  • Laboratory Animals
  • Lymphocytes
  • Maryland
  • Security
  • Viruses

Fields of Study

  • Biology

Readers

  • Immunology

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech